Patents by Inventor Vijay K. Kuchroo

Vijay K. Kuchroo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220152148
    Abstract: Interleukin (IL)-33 is a critical regulator of allergic airway inflammation in the lung and is released by stressed or damaged epithelial cells. Here, Applicants show that alveolar macrophages regulate epithelial alarmin expression via CLEC-2 (C-type Lectin-like Receptor-2), which binds to PDPN (podoplanin). Therefore, CLEC-2/PDPN interactions are critical for regulating type 2 immunity in the lung and modulating expression of the epithelial alarmin IL-33. Methods are disclosed for therapeutic and screening applications. Novel therapeutic targets in alveolar macrophages and epithelial cells are disclosed.
    Type: Application
    Filed: March 18, 2020
    Publication date: May 19, 2022
    Inventors: Patrick R. Burkett, Se-Jin Kim, Samantha J. Riesenfeld, Antonia Wallrapp, Vijay K. Kuchroo, Aviv Regev
  • Publication number: 20220144950
    Abstract: Provided herein are methods and compositions related to the targeting of Bregs for the treatment of diseases and disorders involving inappropriate suppression of B cell-mediated immune function.
    Type: Application
    Filed: March 13, 2020
    Publication date: May 12, 2022
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Vijay K. KUCHROO, Sheng XIAO, Lloyd BOD
  • Publication number: 20220142948
    Abstract: The subject matter disclosed herein is generally directed to modulation of Th17 differentiation and pathogenicity by use of metabolic targets. The metabolic targets are the molecules of the polyamine pathway or glycolysis pathway. Modulation of the polyamine pathway can shift Th17 pathogenicity and shift the transcriptome of Th17 cells to a Treg or Th1 transcriptome. The polyamine analogue DFMO can be used to modulate an inflammatory response. Inhibitors of enzymes in the glycolysis pathway can shift Th17 pathogenicity.
    Type: Application
    Filed: March 18, 2020
    Publication date: May 12, 2022
    Inventors: Aviv Regev, Chao Wang, Vijay K. Kuchroo, Nir Yosef, Allon Wagner, Johannes Fessler
  • Publication number: 20220105135
    Abstract: The present invention is generally directed to identifying genes and cell types that are correlated with tumor progression in the tumor microenvironment. PENK was identified as a therapeutic target that is positively correlated with tumor time and size. Targeting PENK can enhance anti-tumor immunity. Opioid signaling can be modulated to enhance anti-tumor immunity. The present invention is also generally directed to interacting cells in the tumor microenvironment and using the identified interactions to enhance anti-tumor immunity in cancer. Identified interactions can be modulated using therapeutic agents. Immune cells resistant to suppression can be used for adoptive cell transfer.
    Type: Application
    Filed: October 5, 2021
    Publication date: April 7, 2022
    Inventors: Meromit Singer, Aviv Regev, Orit Rozenblatt-Rosen, Davide Mangani, Ana Carrizosa Anderson, Vijay K. Kuchroo, Linglin Huang
  • Publication number: 20210386829
    Abstract: The present invention provides novel compositions and methods based on the discovery of the mechanisms and gene expression programs associated with homeostatic ILC2s and proinflammatory ILC2s that drive tissue inflammation. Molecular cues were identified that modulate ILC responses to alarmins using single-cell RNA-sequencing (scRNA-seq) profiles of lung-resident ILCs at steady state and after in vivo stimulation. The neuropeptide CGRP and the CGRP receptor were identified as expressed on ILC2s. Treatment with CGRP reduces allergic lung inflammation and reduces the proliferation and expansion of ILC2 cells. The results demonstrate that CGRP signaling strongly modulates ILC2 responses and highlights the importance of neuro-immune crosstalk in allergic inflammatory responses at mucosal surfaces.
    Type: Application
    Filed: May 6, 2019
    Publication date: December 16, 2021
    Inventors: Antonia Wallrapp, Patrick R. Burkett, Vijay K. Kuchroo, Aviv Regev, Samantha J. Riesenfeld, Heping Xu
  • Patent number: 11186825
    Abstract: The present invention provides markers, marker signatures and molecular targets that correlate with dysfunction of immune cells and are advantageously independent of the immune cell activation status. The present markers, marker signatures and molecular targets provide for new ways to evaluate and modulate immune responses. Specifically, POU2AF1 modulation is provided for use as a marker, marker signature and molecular target. Therapeutic methods are also provided to treat a patient in need thereof who would benefit from an increased immune response.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: November 30, 2021
    Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.
    Inventors: Aviv Regev, Ana Carrizosa Anderson, Le Cong, Vijay K. Kuchroo, Meromit Singer, Chao Wang
  • Patent number: 11180730
    Abstract: The present invention provides markers, marker signatures and molecular targets that correlate with dysfunction of immune cells and are advantageously independent of the immune cell activation status. The present markers, marker signatures and molecular targets provide for new ways to evaluate and modulate immune responses. Specifically, GATA3 and/or FOXO1 modulation are provided for use as markers, marker signatures and molecular targets. Therapeutic methods are also provided to treat a patient in need thereof who would benefit from an increased immune response.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: November 23, 2021
    Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.
    Inventors: Aviv Regev, Ana Carrizosa Anderson, Le Cong, Vijay K. Kuchroo, Meromit Singer, Chao Wang
  • Publication number: 20210332130
    Abstract: Described herein are novel compositions comprising bispecific and multispecific polypeptide agents, and methods using these agents for targeting cells, such as functionally exhausted or unresponsive immune cells, that co-express the inhibitory receptors PD-1 and TIM-3. These compositions and methods are useful for the treatment of chronic immune conditions, such as persistent infections or cancer.
    Type: Application
    Filed: February 2, 2021
    Publication date: October 28, 2021
    Applicant: The Brigham and Women's Hospital, Inc.
    Inventors: Vijay K. KUCHROO, Ana C. ANDERSON
  • Publication number: 20210317186
    Abstract: Described herein are methods for suppressing an immune response in a subject, e.g., a subject with an autoimmune disease, by administering to the subject a therapeutically effective amount of recombinant CD5L, CD5L homodimers and/or CD5L:p40 heterodimers, or nucleic acids encoding any of these. Also described are methods for enhancing an immune response in a subject, e.g., a subject with cancer, infection, or an immune deficiency, by administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof that binds specifically to CD5L, D5L homodimers and/or CD5L:p40 heterodimers, and inhibits their binding to the IL-23 receptor, or inhibits formation of the CD5L homodimer and/or CD5L:p40 heterodimer, or inhibitory nucleic acids that target CD5L and/or p40.
    Type: Application
    Filed: April 9, 2021
    Publication date: October 14, 2021
    Inventors: Vijay K. Kuchroo, Chao Wang, Aviv Regev, Karthik Shekhar
  • Publication number: 20210263012
    Abstract: The subject matter disclosed herein is generally directed to novel CD8+ and CD4+ T cell subtypes associated with effector, suppressive or regulatory T cell functions. Moreover, the subject matter disclosed herein is generally directed to methods and compositions for use of the subtype. Also, disclosed herein are gene signatures and markers associated with the subtype and use of said signatures and markers. Further disclosed are therapeutic methods of using said gene signatures and immune cell subtype. Further disclosed are pharmaceutical compositions comprising populations of CD4+ and/or CD8+ TILs or populations of immune cells depleted for a specific subtype. Further disclosed are interactions with other T cell subtypes.
    Type: Application
    Filed: November 19, 2018
    Publication date: August 26, 2021
    Inventors: Ana C. Anderson, Vijay K. Kuchroo, Meromit Singer, Aviv Regev
  • Publication number: 20210139601
    Abstract: Described herein are agonists of CD5L monomer, CD5L:CD5L homodimer, and CD5L:p40 heterodimer and compositions and methods for modulating or suppressing an immune response in a subject, e.g. a subject with an autoimmune disease, involving said agonists.
    Type: Application
    Filed: May 25, 2018
    Publication date: May 13, 2021
    Inventors: Vijay K. Kuchroo, Chao Wang, Aviv Regev
  • Patent number: 11001622
    Abstract: Described herein are methods for suppressing an immune response in a subject, e.g., a subject with an autoimmune disease, by administering to the subject a therapeutically effective amount of recombinant CD5L, CD5L homodimers and/or CD5L:p40 heterodimers, or nucleic acids encoding any of these. Also described are methods for enhancing an immune response in a subject, e.g., a subject with cancer, infection, or an immune deficiency, by administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof that binds specifically to CD5L, D5L homodimers and/or CD5L:p40 heterodimers, and inhibits their binding to the IL-23 receptor, or inhibits formation of the CD5L homodimer and/or CD5L:p40 heterodimer, or inhibitory nucleic acids that target CD5L and/or p40.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: May 11, 2021
    Assignees: The Brigham and Women's Hospital, Inc., The Broad Institute, Inc., Massachusetts Institute of Technology
    Inventors: Vijay K. Kuchroo, Chao Wang, Aviv Regev, Karthik Shekhar
  • Publication number: 20210130438
    Abstract: The present invention provides novel pan-cancer T cell exhaustion regulators. CXCR6 expressed in CD8+ T cells was specifically identified as regulating anti-tumor immunity. Modulating CXCR6-CXCL16 interaction is useful in modulating anti-tumor immunity. The identified genes may be modulated in T cells for use in adoptive cell transfer. The identified genes may be modulated in vivo.
    Type: Application
    Filed: October 28, 2020
    Publication date: May 6, 2021
    Inventors: Livnat Jerby-Arnon, Ana Carrizosa Anderson, Aviv Regev, Katherine Tooley, Vijay K. Kuchroo
  • Publication number: 20210130776
    Abstract: The subject matter disclosed herein is generally directed to a novel CD8+ T cell subtype associated with suppressive or regulatory T cell functions. Moreover, the subject matter disclosed herein is generally directed to methods and compositions for use of the subtype. Also, disclosed herein are gene signatures and markers associated with the subtype and use of said signatures and markers. Further disclosed are therapeutic methods of using said gene signatures and immune cell subtype. Further disclosed are pharmaceutical compositions comprising populations of CD8+ TILs depleted for a specific subtype. Further disclosed are interactions with other T cell subtypes.
    Type: Application
    Filed: October 1, 2018
    Publication date: May 6, 2021
    Inventors: Ana Carrizosa Anderson, Vijay K. Kuchroo, Meromit Singer, Aviv Regev
  • Publication number: 20210121530
    Abstract: Computational and functional analysis identified the neuropeptide receptor Nmur1 as selectively expressed on Type 2 innate lymphoid cells (ILC2s). While both IL-33 and IL-25 promote ILC activation in vivo, IL-33 induces robust ILC proliferation, whereas ILCs activated with IL-25 do not proliferate as robustly and up-regulate Nmur1 expression. Treatment with neuromedin U (NMU), the neuropeptide ligand of Nmur1, had little effect on its own. Co-administration of IL-25 with NMU, however, dramatically amplified allergic lung inflammation and induced the proliferation and expansion of specific ILC2 subsets, characterized by a molecular signature unique to pro-inflammatory ILC2s. The results demonstrate that Nmur1 signaling strongly modulates IL-25-mediated ILC2 responses, resulting in highly proliferative pro-inflammatory ILCs, and highlights the importance of neuro-immune crosstalk in allergic inflammatory responses at mucosal surfaces.
    Type: Application
    Filed: March 23, 2018
    Publication date: April 29, 2021
    Inventors: Antonia Wallrapp, Samantha J. Riesenfeld, Patrick R. Burkett, Monika S. Kowalczyk, Aviv Regev, Vijay K. Kuchroo
  • Publication number: 20210102166
    Abstract: The subject matter disclosed herein is generally directed to tissue specific modulation of Th17 differentiation and pathogenicity by targeting tissue specific Th17 gene programs and gene targets. The tissue specific modulation may be used therapeutically to treat a disease or condition in the tissue where it arises. The subject matter disclosed herein is also directed to detecting tissue specific Th17 cells for diagnostic and therapeutic methods.
    Type: Application
    Filed: October 5, 2020
    Publication date: April 8, 2021
    Inventors: Meromit Singer, Alexandra Schnell, Aviv Regev, Vijay K. Kuchroo
  • Publication number: 20210100774
    Abstract: The subject matter disclosed herein is generally directed to modulating anti-tumor T cell immunity by modulating steroidogenesis. Steroidogenesis may be modulated with inhibitors of enzymes that synthesize glucocorticoids in a tumor. The inhibitor may target Cyp11a1. The inhibitor may be metyrapone. The invention further relates to modulating immune states, such as CD8 T cell immune states, in vivo, ex vivo and in vitro. The invention further relates to diagnostic and screening methods.
    Type: Application
    Filed: October 7, 2020
    Publication date: April 8, 2021
    Inventors: Ana Carrizosa Anderson, Asaf Madi, Nandini Acharya, Vijay K. Kuchroo, Aviv Regev
  • Publication number: 20210102168
    Abstract: The present invention is generally directed to identify interacting cells in the tumor microenvironment and using the identified interactions to enhance anti-tumor immunity in cancer. Identified interactions can be modulated using therapeutic agents. Immune cells resistant to suppression can be used for adoptive cell transfer. The present invention is also generally directed to cell types and genes that are correlated to time of tumor growth and tumor size.
    Type: Application
    Filed: October 5, 2020
    Publication date: April 8, 2021
    Inventors: Meromit Singer, Aviv Regev, Orit Rozenblatt-Rosen, Davide Mangani, Ana Carrizosa Anderson, Vijay K. Kuchroo, Linglin Huang
  • Patent number: 10934352
    Abstract: Described herein are novel compositions comprising bispecific and multispecific polypeptide agents, and methods using these agents for targeting cells, such as functionally exhausted or unresponsive immune cells, that co-express the inhibitory receptors PD-1 and TIM-3. These compositions and methods are useful for the treatment of chronic immune conditions, such as persistent infections or cancer.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: March 2, 2021
    Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Vijay K. Kuchroo, Ana C. Anderson
  • Publication number: 20210047694
    Abstract: The present invention is generally directed to a colorectal (CRC) cell atlas that provides methods of predicting outcomes of cancer patients and therapeutic targets for treating patients in need thereof. The atlas may be used to predict a response to immunotherapy, in particular checkpoint blockade therapy and adoptive cell transfer. Disclosed herein are previously unidentified gene programs in tumors that can be used to predict response and provide for therapeutic targets that can be used to shift a tumor to a responsive phenotype.
    Type: Application
    Filed: August 17, 2020
    Publication date: February 18, 2021
    Inventors: Aviv Regev, Nir Hacohen, Vijay K. Kuchroo, Ana Carrizosa Anderson, Orit Rozenblatt-Rosen, Jonathan Chen, Karin Pelka, Matan Hofree